Keywords
Hepatitis C virus (HCV) infection, HCV infection-related diseases, statins, replicon system, human hepatocyte-like cells from human induced pluripotent stem cells, direct-acting antiviral agents (DAAs)
Hepatitis C virus (HCV) infection, HCV infection-related diseases, statins, replicon system, human hepatocyte-like cells from human induced pluripotent stem cells, direct-acting antiviral agents (DAAs)
All of the author names were updated to correct them and the order of the authors was also corrected.
See the authors' detailed response to the review by Joel D. Baines
Hepatitis C virus (HCV) infection is an important public health problem worldwide, as many HCV-infected patients develop liver cirrhosis and/or hepatocellular carcinoma (HCC)1.
Recent improvements in the treatment of HCV infection have focused on the use of direct-acting antiviral agents (DAAs)1. However, despite successful viral clearance, many patients with advanced fibrosis continue to have HCV-related disease progression2,3. Therefore, new treatments must be developed to achieve viral clearance and prevent the risk of HCV-related diseases.
Statins (inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase) have been proposed as a new candidate for the treatment of HCV infection. According to previously conducted clinical studies using statins in HCV-infected patients4–8, the antiviral effect of statins on HCV infection depends on the type of statin used. Among various statins, pitavastatin showed the highest antiviral efficacy against HCV genotype 1b infection in vitro9. Therefore, pitavastatin represents a novel candidate for the treatment of HCV infection.
After performing a search of the PubMed database, we identified three clinical trials using pitavastatin for the treatment of HCV infection7,8,10.
When Shimada et al.7 considered two reports published in 2010 investigating the antiviral efficacy of pitavastatin against HCV infection in vitro9,11, they conducted a randomized controlled trial7. The proof-of-concept studies demonstrated the antiviral efficacy and safety of pitavastatin against HCV infection using a replicon system and human hepatocyte-like cells from human induced pluripotent stem cells (hiPSCs)9,11, and these effects of pitavastatin were confirmed in the randomized controlled trial7,12. Indeed, this series of studies7,9,11 would be the first to report the clinical applications of hiPSCs12. After the clinical trial performed by Shimada et al.7, the antiviral efficacy and safety of pitavastatin against HCV infection were further confirmed in two clinical studies8,10. Thus, investigating the antiviral efficacy and safety of pitavastatin against HCV infection using a replicon system and human hepatocyte-like cells from hiPSCs9,11 constitutes a rational approach to discover new drugs and/or new therapeutic methods.
Butt et al.13 showed that statin use was associated with improved antiviral efficacy as well as decreased progression of liver fibrosis and a reduced incidence of HCC among a large cohort of HCV-positive veterans. Furthermore, the use of statins among patients with HCV and compensated cirrhosis (n=40,512) was associated with a more than 40% lower risk of cirrhosis decomposition and death14. Moreover, statin users showed a significant reduction in the incidence of HCC15. In addition, pitavastatin showed anti-cancer effects against human hematoma cell lines16–18.
DAAs in combination with statins have been shown to generate increased antiviral efficacy against HCV infection19. However, concerns have been raised about the drug interactions between various statins and DAAs20. For instance, simvastatin and lovastatin should be avoided in patients with HCV infection who are using boceprevir or telaprevir as a DAA21. Atorvastatin should be avoided in patients with HCV infection who are using telaprevir21, and pravastatin plus boceprevir may also pose risks21. Although rosuvastatin could be considered for use in combination with telaprevir and boceprevir21, the drug interactions between pitavastatin and DAAs remain unknown.
Furthermore, according to our search of the PubMed database and UMIN Clinical Trials Registry System (http://www.umin.ac.jp/icdr/index.html), no clinical trial has been conducted for the combination of statins and DAAs. Therefore, although there is likely only a minimal additive benefit for viral clearance using statins, as new combinations of DAA (sofosbuvir and velpatasvir) therapy have shown sustained virologic response (SVR) rates above 95%22, conducting a clinical trial for the combination of pitavastatin and DAAs may be meaningful to investigate management methods to prevent fibrosis and cirrhosis or the development of HCC and other HCV-related diseases in the era of DAAs. However, in pre-clinical trials, the antiviral effects of the combination of pitavastatin and DAAs should be evaluated using a replicon system9. Furthermore, hepatotoxicities should also be evaluated for the combination of pitavastatin and DAAs using human hepatocyte-like cells from hiPSCs11. Using a replicon system and human hepatocyte-like cells from hiPSCs in a pre-clinical trial9,11, an optimal direct-acting antiviral agent could be selected for use in the combination of pitavastatin and DAAs. After the pre-clinical trial, the combination of pitavastatin and the optimal direct-acting antiviral agent should be compared with other DAA combinations (e.g., sofosbuvir and velpatasvir) according to their antiviral efficacy against HCV infection and prevention of HCV-related diseases. Furthermore, because the cost for DAA combination treatment is very high ($83,000 to $153,000 per course of treatment)22, the new and effective hepatitis C treatments seem beyond the reach of low- and middle-income countries23. However, the cost ($0.79 to $2.59 per day) of pitavastatin (2mg)7 is low (http://www.pharmacychecker.com/generic/price-comparison/pitavastatin/2+mg/). Therefore, the above-mentioned comparison should also be investigated in light of cost-effectiveness.
On the other hand, a replicon system in hepatocellular cells is not likely to duplicate the full gamut of potential side effects seen in patients with HCV infection receiving pitavastatin and DAAs. The risks (potential side effects) that will not be revealed in a pre-clinical trial using this system should be acknowledged. Therefore, in order to identify the risk (potential side effects) that will not be revealed in a pre-clinical trial using this system, the evaluations using human neurons and human cardiomyocytes from hiPSCs24,25 should also be done in pre-clinical trials.
In conclusion, a pre-clinical trial investigating the combination of pitavastatin and DAAs against HCV infection using a replicon system, human hepatocyte-like cells, human neurons and human cardiomyocytes from hiPSCs9,11,24,25 represents a rational approach for discovering a new therapeutic method.
All authors (Reem Mohamed Fathy EI-Shenawy, Sara Kishta and Sobhy Kishta) equally contributed to the writing of the manuscript.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 3 (revision) 25 Jan 17 |
||
Version 2 (revision) 07 Jul 16 |
read | |
Version 1 26 Feb 16 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)